AGP Executive Report
Last update: 7 hours agoMedical Cannabis Research Funding: Canada is putting $24M into a national cannabis-and-brain-health consortium via CIHR, aiming to clarify how use affects mental health and wellbeing across youth, pregnancy, and frequent users. Clinical CBD/Medical Trials: Avicanna reported Q2 2026 results, highlighting growth in proprietary product sales and progress toward a Q3 launch tied to its QUIX™ platform. Regulatory/Access: A Rhode Island federal judge dissolved an order blocking the state’s social equity and adult-use cannabis licensing program after changes to state law mooted the earlier challenge. Public Health & Safety (Kratom): Massachusetts moved to crack down hard on kratom with an emergency order placing products into Schedule I under state law, citing serious health risks and inconsistent potency. Global Drug-War Accountability: The Philippines’ Duterte drug-war truth commission opened hearings with testimony from a mother whose son was killed over alleged marijuana and shabu dealing. CBD Market/Labeling Watch: A consumer-focused piece urges better labeling and lab-report access for delta-8 THC products, warning that sourcing and testing standards can vary.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
